Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up…
Sanofi-backed Expedition lands $115M for ph. 2 COPD tria
Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to…
Sanofi replaces R&D chief as new CEO seeks to kickstart pipeline
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring former Roche executive Paulo Fontoura,…
Sanofi won’t seek approval for eczema drug from Kymab buyout
Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis (AD), admitting that a drug once…
Sanofi CEO ‘looking deeply’ at pipeline as clearout continues
When Belén Garijo, M.D., Ph.D., left the top job at Germany’s Merck KGaA to head over to Sanofi,…
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has…
Corbus posts obesity data in area where Novo, Sanofi stumbled
Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence that its CB1 inverse agonist may be less prone to…
Say what you like about the competition! No fines for Sanofi in EC disparagement case, Sean-Paul Brankin
On 26 June, the European Commission (EC) announced the opening of a competition law investigation into allegations of a campaign…
MacroGenics to get $24.5M Sanofi milestone
MacroGenics (NASDAQ: MGNX) will receive a $24.5 million regulatory milestone payment from Sanofi…
Sanofi bispecific sees respiratory ph. 2 wins, eczema fail
Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on…
Astellas appoints new top strategist—Chutes & Ladders
Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the…
Sanofi returns to TCEs via $1.2B pact for ph. 1-stage trispecific
Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near…